News

Fierce Biotech16m

Private equity firm acquires clinical trial site network Headlands Research

After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself.  | After ...
Fierce Biotech3h

Stealth Bio submits third FDA application for rare disease candidate

After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational ...
Fierce Biotech3h

Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...
Fierce Biotech4h

Merck KGaA swoops into Skyhawk neurological disease pact worth up to $2B

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...
Fierce Biotech3h

Baxter’s Novum IQ corrections grow in scope to include syringe pumps

Baxter’s efforts this summer to correct high-risk issues with its infusion pumps has gotten more complicated.  | Last month ...
Fierce Biotech6h

Reunion’s psychedelic prodrug reduces postpartum depression symptoms in ph. 2 study

Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the ...
Fierce Biotech6h

Pfizer’s SCD drug fails ph. 3 study in latest blow to Global Blood Therapeutics' legacy

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...
Fierce Biotech3h

Neurizon becomes second biotech hit with FDA delay for ALS candidate

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | Yet another biotech is facing a delay from the Food and Drug ...